Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

Agha, Douâa Moussa; Rouas, Rédouane; Najar, Mehdi; Bouhtit, Fatima; Naamane, Najib; Fayyad‐Kazan, Hussein; Bron, Dominique; Meuleman, Nathalie; Lewalle, Philippe; Merimi, Makram

doi:10.3390/ijms21197065

Cited by 13 publications

(4 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNAs, such as CML LSC-supporting miR-126, are often shuttled via EVs (miR-126 from endothelial cells) [ 153 ], increasing their relevance and applicability for biomarker studies. High throughput studies have identified miRNAs and lncRNAs enriched in AML cells, and revealed that these may be involved in modulating both T cell [ 154 ] and NK cell responses [ 155 ]. Interestingly, miR-300 was crucial not only for LSCs pro-leukemic properties, but also impaired NK cells effector function in CML.…”

Section: Leukemia-derived Factors That Promote Immune Evasionmentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

Both chronic myeloid leukemia and acute myeloid leukemia evade the immune response during their development and disease progression. As myeloid leukemia cells modify their bone marrow microenvironment, they lead to dysfunction of cytotoxic cells, such as CD8+ T cells or NK cells, simultaneously promoting development of immunosuppressive regulatory T cells and suppressive myeloid cells. This facilitates disease progression, spreading of leukemic blasts outside the bone marrow niche and therapy resistance. The following review focuses on main immunosuppressive features of myeloid leukemias. Firstly, factors derived directly from leukemic cells – inhibitory receptors, soluble factors and extracellular vesicles, are described. Further, we outline function, properties and origin of main immunosuppressive cells - regulatory T cells, myeloid derived suppressor cells and macrophages. Finally, we analyze interplay between recovery of effector immunity and therapeutic modalities, such as tyrosine kinase inhibitors and chemotherapy.

show abstract

Section: Leukemia-derived Factors That Promote Immune Evasionmentioning

confidence: 99%

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Swatler

Turos-Korgul

Kozłowska

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Breast cancer [ 53 ], prostate cancer [ 54 ], lung cancer [ 55 ], gastric cancer [ 56 ], colorectal carcinoma [ 57 ], hepatocellular carcinoma [ 58 ], and squamous cell carcinoma of the esophagus [ 59 ] have all been associated with abnormal miR-106b expression. In the context of leukemia, in a recent study, Moussa Agha et al [ 60 ] investigated the circulating miRNA profile in 27 patients with bone marrow acute myeloid leukemia (AML) at the time of diagnosis and at the first complete remission after treatment compared with 11 healthy donors. The results showed that several miRNAs, including miR-106b, were deregulated among the three groups and were associated with tumor progression and immunosuppression.…”

Section: Discussionmentioning

confidence: 99%

Small RNA Profiling in an HTLV-1-Infected Patient with Acute Adult T-Cell Leukemia-Lymphoma at Diagnosis and after Maintenance Therapy: A Case Study

Pessôa

Souza

Nukui

et al. 2023

IJMS

View full text Add to dashboard Cite

Small RNAs (sRNAs) are epigenetic regulators of essential biological processes associated with the development and progression of leukemias, including adult T-cell leukemia/lymphoma (ATLL) caused by human T-cell lymphotropic virus type 1 (HTLV-1), an oncogenic human retrovirus originally discovered in a patient with adult T-cell leukemia/lymphoma. Here, we describe the sRNA profile of a 30-year-old woman with ATLL at the time of diagnosis and after maintenance therapy with the aim of correlating expression levels with response to therapy.

show abstract

“…A study of bone marrow circulating miRNAs in AML found that miR-423-5p was overexpressed in AML bone marrow samples. 37 Moreover, MiR-423 (among other miRNAs) was overexpressed in two AML cell lines HL-60 (human promyelocytic leukemia cell line) and THP-1 (human monocytic leukemia cell line). 38 Merkerova et al studied the miRNA expression profile of 1145 miRNAs in CD34+ cells of MDS patients and found that hsa-miR-423-5p was downregulated in those patients.…”

Section: Discussionmentioning

confidence: 99%

Circulating miR-126-3p and miR-423-5p Expression in de novo Adult Acute Myeloid Leukemia: Correlations with Response to Induction Therapy and the 2-Year Overall Survival

Almohsen¹,

Al-Rubaie²,

MA³

et al. 2022

JBM

View full text Add to dashboard Cite

Background Acute myeloid leukemia (AML) results from sequential genetic alterations in a normal hematopoietic stem cell or its progenitors giving rise to an autonomous clone that dominates the bone marrow leading to marrow failure. MicroRNAs are short non-coding nucleic acid sequences that regulate post-transcriptional gene expression by base-pairing with their target mRNAs. MiRNAs can be secreted into extracellular fluids and carried to target cells by vesicles or bound to proteins. Intracellular and circulating miRNAs are believed to be useful markers in the diagnosis, prognosis, and treatment of various cancers. Practically, circulating miRNAs are more stable at room temperatures and extreme conditions. Purpose This study aimed to compare the expression of miR-126-3p and miR-423-5p in patients and normal subjects and correlate their expression with response to induction therapy and with their 2-year overall survival rate. Patients and Methods Circulating miR-126-3p and miR-423-5p was measured in the plasma of 43 adult AML patients and 35 age- and sex-matched controls by quantitative reverse transcriptase PCR. The fold change in differential expression for each gene was calculated using the comparative cycle threshold method. Results There was an increase in the expression of the studied miRNAs in patients compared to the control group. The average expression fold change of miR-126-3p was 3.02 ( p = 0.010). The average expression fold change of miR-423-5p was 4.09 ( p = 0.003). No significant correlation was found between the expression of miR-126-3p and miR-423-5p in the studied AML patients (r = 0.094, p = 0.22). Furthermore, no relationship was found between the expression of the studied miRNAs and response to induction therapy or the 2-year survival rate. Conclusion Although further studies are needed, our findings highlight the studied circulating miRNAs as possible diagnostic markers for AML.

show abstract

Identification of Acute Myeloid Leukemia Bone Marrow Circulating MicroRNAs

Cited by 13 publications

References 108 publications

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

Small RNA Profiling in an HTLV-1-Infected Patient with Acute Adult T-Cell Leukemia-Lymphoma at Diagnosis and after Maintenance Therapy: A Case Study

Circulating miR-126-3p and miR-423-5p Expression in de novo Adult Acute Myeloid Leukemia: Correlations with Response to Induction Therapy and the 2-Year Overall Survival

Contact Info

Product

Resources

About